Literature DB >> 22547109

Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.

Bisrat G Debeb1, Evan N Cohen, Kimberly Boley, Erik M Freiter, Li Li, Fredika M Robertson, James M Reuben, Massimo Cristofanilli, Thomas A Buchholz, Wendy A Woodward.   

Abstract

Basal breast cancer, common among patients presenting with inflammatory breast cancer (IBC), has been shown to be resistant to radiation and enriched in cancer stem cells. The Notch pathway plays an important role in self-renewal of breast cancer stem cells and contributes to inflammatory signaling which promotes the breast cancer stem cell phenotype. Herein, we inhibited Notch signaling using a gamma secretase inhibitor, RO4929097, in an in vitro model that enriches for cancer initiating cells (3D clonogenic assay) and conventional 2D clonogenic assay to compare the effect on radiosensitization of the SUM149 and SUM190 IBC cell lines. RO4929097 downregulated the Notch target genes Hes1, Hey1, and HeyL, and showed a significant reduction in anchorage independent growth in SUM190 and SUM149. However, the putative self-renewal assay mammosphere formation efficiency was increased with the drug. To assess radiosensitization of putative cancer stem cells, cells were exposed to increasing doses of radiation with or without 1 μM RO4929097 in their standard (2D) and self-renewal enriching (3D) culture conditions. In the conventional 2D clonogenic assay, RO4929097 significantly sensitized SUM190 cells to ionizing radiation and has a modest radiosensitization effect in SUM149 cells. In the 3D clonogenic assays, however, a radioprotective effect was seen in both SUM149 and SUM190 cells at higher doses. Both cell lines express IL-6 and IL-8 cytokines known to mediate the efficacy of Notch inhibition and to promote self-renewal of stem cells. We further showed that RO429097 inhibits normal T-cell synthesis of some inflammatory cytokines, including TNF-α, a potential mediator of IL-6 and IL-8 production in the microenvironment. These data suggest that additional targeting agents may be required to selectively target IBC stem cells through Notch inhibition, and that evaluation of microenvironmental influences may shed further light on the potential effects of this inhibitor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22547109      PMCID: PMC4545650          DOI: 10.1007/s10549-012-2075-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  60 in total

1.  Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor.

Authors:  G S Rao; S Murray; S P Ethier
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

2.  TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.

Authors:  Gianluca Storci; Pasquale Sansone; Sara Mari; Gabriele D'Uva; Simona Tavolari; Tiziana Guarnieri; Mario Taffurelli; Claudio Ceccarelli; Donatella Santini; Pasquale Chieco; Kenneth B Marcu; Massimiliano Bonafè
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

3.  Blockage of Notch1 signaling modulates the T-helper (Th)1/Th2 cell balance in chronic hepatitis B patients.

Authors:  Jinxian Pei; Zhenghao Tang; Guoqing Zang; Yongsheng Yu
Journal:  Hepatol Res       Date:  2010-07-07       Impact factor: 4.288

4.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

Review 5.  Examining the metastatic niche: targeting the microenvironment.

Authors:  Theresa Guise
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

6.  Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions.

Authors:  Bisrat G Debeb; Wei Xu; Henry Mok; Li Li; Fredika Robertson; Naoto T Ueno; Jim Reuben; Anthony Lucci; Massimo Cristofanilli; Wendy A Woodward
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

Review 7.  Functions of notch signaling in the immune system: consensus and controversies.

Authors:  Julie S Yuan; Philaretos C Kousis; Sara Suliman; Ioana Visan; Cynthia J Guidos
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

Review 8.  Polarized immune responses differentially regulate cancer development.

Authors:  Magnus Johansson; David G Denardo; Lisa M Coussens
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

9.  IL-6 production by human T lymphocytes. Expression in HTLV-1-infected but not in normal T cells.

Authors:  P M Villiger; M T Cronin; T Amenomori; W Wachsman; M Lotz
Journal:  J Immunol       Date:  1991-01-15       Impact factor: 5.422

10.  Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.

Authors:  Hannah Harrison; Gillian Farnie; Sacha J Howell; Rebecca E Rock; Spyros Stylianou; Keith R Brennan; Nigel J Bundred; Robert B Clarke
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

View more
  28 in total

1.  Bruceantin inhibits multiple myeloma cancer stem cell proliferation.

Authors:  Mark E Issa; Sarah Berndt; Gilles Carpentier; John M Pezzuto; Muriel Cuendet
Journal:  Cancer Biol Ther       Date:  2016-07-19       Impact factor: 4.742

Review 2.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

3.  A personalized committee classification approach to improving prediction of breast cancer metastasis.

Authors:  Md Jamiul Jahid; Tim H Huang; Jianhua Ruan
Journal:  Bioinformatics       Date:  2014-03-10       Impact factor: 6.937

4.  Activation of Notch3 in Glomeruli Promotes the Development of Rapidly Progressive Renal Disease.

Authors:  Fala El Machhour; Zela Keuylian; Panagiotis Kavvadas; Jean-Claude Dussaule; Christos Chatziantoniou
Journal:  J Am Soc Nephrol       Date:  2014-11-24       Impact factor: 10.121

Review 5.  New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Authors:  Armel Hervé Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Richard Simo Tagne; Jeremie Mbo Amvene; Jean-Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

6.  Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

Authors:  Jennifer L Allensworth; Myron K Evans; François Bertucci; Amy J Aldrich; Richard A Festa; Pascal Finetti; Naoto T Ueno; Rachid Safi; Donald P McDonnell; Dennis J Thiele; Steven Van Laere; Gayathri R Devi
Journal:  Mol Oncol       Date:  2015-02-21       Impact factor: 6.603

7.  Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

Authors:  Kevin P Williams; Jennifer L Allensworth; Shalonda M Ingram; Ginger R Smith; Amy J Aldrich; Jonathan Z Sexton; Gayathri R Devi
Journal:  Cancer Lett       Date:  2013-05-17       Impact factor: 8.679

Review 8.  Rethinking Gamma-secretase Inhibitors for Treatment of Non-small-Cell Lung Cancer: Is Notch the Target?

Authors:  Sharon R Pine
Journal:  Clin Cancer Res       Date:  2018-08-13       Impact factor: 12.531

9.  γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.

Authors:  Margot J Pont; Tyler Hill; Gabriel O Cole; Joe J Abbott; Jessica Kelliher; Alexander I Salter; Michael Hudecek; Melissa L Comstock; Anusha Rajan; Bharvin K R Patel; Jenna M Voutsinas; Qian Wu; Lingfeng Liu; Andrew J Cowan; Brent L Wood; Damian J Green; Stanley R Riddell
Journal:  Blood       Date:  2019-11-07       Impact factor: 22.113

10.  IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer.

Authors:  Dong Wang; Jiahui Xu; Bingjie Liu; Xueyan He; Lei Zhou; Xin Hu; Feng Qiao; Anli Zhang; Xiaojun Xu; Huafeng Zhang; Max S Wicha; Lixing Zhang; Zhi-Ming Shao; Suling Liu
Journal:  Cell Death Differ       Date:  2017-10-13       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.